92138-10-8 Usage
Uses
Used in Neuroscience Research:
ZAPA Sulfate is used as a research tool for studying the role of GABA receptors, specifically those linked to benzodiazepine receptors. Its agonistic properties allow scientists to investigate the mechanisms of action and potential therapeutic applications related to these receptors.
Used in Pharmaceutical Development:
In the pharmaceutical industry, ZAPA Sulfate may be utilized in the development of new drugs targeting GABAergic systems. Its ability to modulate low affinity GABAA receptors could lead to the discovery of novel therapeutic agents for the treatment of various neurological and psychiatric disorders.
Used in Drug Screening:
ZAPA Sulfate can be employed in drug screening assays to identify potential lead compounds that interact with GABA receptors. This can aid in the development of new medications with improved efficacy and reduced side effects.
Overall, (Z)-3-[(AMINOIMINOMETHYL)THIO]PROP-2-ENOIC ACID SULFATE is a valuable compound in the study and potential treatment of disorders related to GABAergic neurotransmission. Its applications in research, pharmaceutical development, and drug screening highlight its importance in advancing our understanding of GABA receptor function and its role in health and disease.
Biological Activity
More potent than either GABA or muscimol as an agonist at low affinity GABA A receptors and is thus a useful ligand to investigate GABA receptors linked to benzodiazepine receptors. Also a GABA C receptor antagonist.
Check Digit Verification of cas no
The CAS Registry Mumber 92138-10-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,1,3 and 8 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 92138-10:
(7*9)+(6*2)+(5*1)+(4*3)+(3*8)+(2*1)+(1*0)=118
118 % 10 = 8
So 92138-10-8 is a valid CAS Registry Number.
InChI:InChI=1/C4H6N2O2S.H2O4S/c5-4(6)9-2-1-3(7)8;1-5(2,3)4/h1-2H,(H3,5,6)(H,7,8);(H2,1,2,3,4)/b2-1-;
92138-10-8Relevant academic research and scientific papers
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: Discovery of a novel aminoguanidinoacetic acid antidiabetic agent
Larsen,Connell,Cudahy,Evans,May,Meglasson,O'Sullivan,Schostarez,Sih,Stevens,Tanis,Tegley,Tucker,Vaillancourt,Vidmar,Watt,Yu
, p. 1217 - 1230 (2007/10/03)
3-Guanidinopropionic acid (1, PNU-10483) has been demonstrated to both improve insulin sensitivity and to promote weight loss selectively from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM). However, 1 has also been shown to be a substrate for both the creatine transporter and creatine kinase, leading to marked accumulation in muscle tissue as the corresponding N-phosphate 4. In an effort to identify novel entities that maintain antidiabetic potency without susceptibility to creatine-like metabolism, an analogue program was undertaken to explore the effects of various structural modifications, including homologation, simple substitution, single atom mutations, and bioisosteric replacements for the guanidine and carboxylic acid. Overall, the scope of activity encompassed by the set of new analogues proved to be exceedingly narrow. Notable exceptions demonstrating equivalent or improved antidiabetic activity included the α-amino derivative 29, aminopyridine 47, isothiourea 67, and aminoguanidine 69. On the basis of its superior therapeutic ratio, aminoguanidine 69 was selected for preclinical development and became the foundation for a second phase of analogue work. Furthermore, in vitro studies demonstrated that 69 is markedly less susceptible to phosphorylation by creatine kinase than the lead 1, suggesting that it should have less potential for accumulation in muscle tissue than 1.
